BioSpace News Archive

Altos Labs (Altos) today announced that Herbert “Skip” Virgin, MD, PhD, will join the company as Chief Medical Officer and Head of the Altos Institute.

Interventional Orthopedic Solutions Rochester is establishing its commitment to excellence in the field of Regenerative Orthopedics by entering into a partnership with Regenexx®, a worldwide network of specially trained physicians providing advanced, research-driven, regenerative orthopedic treatments.

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced new two-year data from the TENAYA and LUCERNE studies that reinforce the long-term efficacy, safety and durability of Vabysmo® (faricimab-svoa) in wet, or neovascular, age-related macular degeneration (AMD), a leading cause of vision loss.

Gevo, Inc. (NASDAQ: GEVO) announced today that it will host a conference call on Monday, August 8, 2022, at 4:30 p.m. EDT (2:30 p.m. MDT) to report its financial results for the second quarter ended June 30, 2022 and provide an update on recent corporate highlights.

Chiesi, the international research-focused biopharmaceutical group, released its Annual and Sustainability Report for 2021.

Xequel Bio, Inc. announced positive results from its Phase 1b clinical trial with iNexin™ (aCT1 ophthalmic solution) for the treatment of corneal injury in patients with dry eye disease.

oday, at HA Connect!, the 17th annual national conference on hydrocephalus, Hyperfine—creator of Swoop ®, the first FDA-cleared portable magnetic resonance imaging (MRI) device—announced a new software enhancement that enables brain scans in under three minutes with no ionizing radiation.

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a clinical-stage life sciences company that is focused on the development of immunologic‑based therapies for the prevention and treatment of disease, today announced data base lock for its Phase 1b CLEAR clinical study to evaluate the effect of intranasal REVTx-99b on nasal challenge allergen in participants with allergic rhinitis to rye grass pollen.

MDbio are a leading plant-based, wellness solution who provide safe, pharmaceutical-grade products and medicines. Founded by four medical doctors with notable and successful careers at premier American hospitals and medical centers, their goal is to create products and medicines that have transparent efficacy trial data and abide by the strictest manufacturer processes.

Biora Therapeutics, Inc . (Nasdaq: BIOR), the biotech company that is reimagining therapeutics, today shared two posters that were presented at the Controlled Release Society (CRS) 2022 Annual Meeting, which is being held July 11-15, 2022, in Montreal, Canada.